Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

Abstract Background A 12-dose, once-weekly regimen of isoniazid and rifapentine (3HP) is effective in preventing tuberculosis (TB) among people living with HIV (PLHIV). We sought to identify potential barriers to and facilitators of acceptance and completion of 3HP treatment from the perspective of...

Full description

Bibliographic Details
Main Authors: Fred C. Semitala, Allan Musinguzi, Jackie Ssemata, Fred Welishe, Juliet Nabunje, Jillian L. Kadota, Christopher A. Berger, Achilles Katamba, Noah Kiwanuka, Moses R. Kamya, David Dowdy, Adithya Cattamanchi, Anne R. Katahoire
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Implementation Science Communications
Subjects:
Tuberculosis
Preventive therapy
Perceived barriers
Perceived facilitators
People living with HIV
Health workers
Online Access:https://doi.org/10.1186/s43058-021-00173-2

Similar Items

Similar Items